GS-1811 is a potentially first-in-class immunotherapy designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in tumors.
The use of PAPRs and SARs is increasing due to potential drug potency exposures during manufacturing and greater awareness of respiratory technology advances.
The new site is focused on providing early-stage R&D services including chemical process development, pre-formulation study and formulation development.
Will leverage AbCellera’s antibody discovery and development engine to deliver optimized candidates for targets selected by AbbVie across multiple indications.
Will focus on supporting the clinical trials of clients who are developing cell and gene therapies around the world and across multiple therapeutic areas.
Streamlining sample management, ensuring proper storage practices across the full chain of custody, and harmonizing data collection, storage and inventory.
Precision Mutant Library service aims to create a more precise and diverse mutant library that contains all desired variants with unbiased distribution.
Will leverage HotSpot's Smart Allostery drug discovery platform for the development of the first small molecule IRF5 for the treatment of autoimmune diseases.
Aims to use research and innovation to grow Singapore's manufacturing capabilities for biologics, including recombinant therapeutic proteins, and vaccines.